S. Ahn

Prognostic implication of tumor grade in patients with node-negative breast cancer aged ≤ 50 years with 21-gene recurrence scores of 11-25.
20260 citationsauthor #7
Clinical relevance of clinical treatment score post-5 years (CTS5) in HR-positive, HER2-positive breast cancer
20251 citationsauthor #7
Response to "The Impact of Baseline Comorbidities and Performance Status on HER2-Targeted Therapy Outcomes".
20250 citationsauthor #2
Influence of psychological factors on the benefit from interpectoral and pectoserratus plane block for recovery after partial mastectomy: a randomized controlled trial
20250 citationsauthor #10
Spatial analysis of tumor immune microenvironment of TNBC with different neoadjuvant chemotherapy outcomes using multiplex Immunofluorescence
20250 citationsauthor #6
Body mass index and progesterone receptor in postmenopausal ER-positive/HER2-negative breast cancer: A nation-wide study in Korean breast cancer society and the multi-institutional cohort
20250 citationsauthor #19
Abstract P1-04-28: Comparison of tumor immune microenvironment of TNBC with different treatment outcome with neoadjuvant chemotherapy: Spatial analysis using multiplex fluorescent immunohistochemistry
20250 citationsauthor #8
Author Correction: Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
20250 citationsauthor #7
Long-term oncologic outcome of intraoperative radiotherapy (IORT) with low-energy X-rays as a tumor-bed boost in Korean patients with breast cancer.
20250 citationsauthor #5
Impact of treatment response to neoadjuvant chemotherapy on brain metastasis patterns and breast cancer prognosis
20250 citationsauthor #3
Preoperative Predictors of Subsequent Breast Cancer Events Detected on Abbreviated MRI in Patients with Early-Stage Breast Cancer
20250 citationsauthor #6
Effect of body mass index on the prognostic impact of progesterone receptor in postmenopausal ER+HER2- breast cancer: A nationwide study in Korean Breast Cancer Society and multi-institutional cohort.
20250 citationsauthor #1
Pathological complete response, histologic grade, and level of stromal tumor-infiltrating lymphocytes in ER + HER2- breast cancer
20252 citationsauthor #7
Distinct cellular interactions in the TNBC tumor microenvironment in association with PD-L1 expression and pathologic complete response based on spatial analysis.
20250 citationsauthor #1
Abstract P3-02-06: Prevalence of BRCA1/2 Mutations in Low ER Positive/HER2 Negative Breast Cancer: Clinico-Pathological Parameters and Comparisons with Unselected TNBC
20250 citationsauthor #5
Abstract P4-11-17: Prognostic significance of complete cell cycle arrest compared to the CPS + EG scoring system in patients with HR+/HER2- breast cancer receiving neoadjuvant chemotherapy
20250 citationsauthor #2
Decision-Making Patterns for Clinically Node-Positive, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: Insights From a Survey of Breast Cancer Experts
20250 citationsauthor #7
Additional prognostic value of the BCT score in ER+HER2- breast cancer patients receiving a 21-gene assay-guided adjuvant treatments
20251 citationsauthor #1
Abstract PS6-05: First report of clinicopathologic characteristics and surgical outcomes of patients in the Avoid axillary Sentinel Lymph node biopsy After Neoadjuvant chemotherapy (ASLAN) trial (KBCSG-28)
20250 citationsauthor #5
Feasibility of Intraoperative Radiotherapy Tumor Bed Boost in Patients with Breast Cancer after Neoadjuvant Chemotherapy
20244 citationsauthor #5
Abstract PO4-03-05: Prognostic value of Ki67 expression in post-treatment tumors of patients with residual triple-negative breast cancer after neoadjuvant chemotherapy
20240 citationsauthor #11
Abstract PO2-08-05: ERBB2 mutated breast cancer detected by next generation sequencing: integrated analysis based on real-world data and The Cancer Genome Atlas
20240 citationsauthor #10
Dural Metastasis in Breast Cancer: MRI-Based Morphological Subtypes and Their Clinical Implications
20243 citationsauthor #6
Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2+ early breast cancer (EBC).
20244 citationsauthor #3
Abstract PO3-28-06: YAP1 expression is a good prognostic marker of hormone receptor-positive HER2-negative breast cancer: clinicopathologic analysis using the 21-gene recurrent score
20240 citationsauthor #5
Abstract PO3-07-06: Correlation between residual microcalcification and in-breast pathologic response in relation to MRI response and the subtypes after neoadjuvant chemotherapy
20241 citationsauthor #9
Age and Late Recurrence in Young Patients With ER–Positive, ERBB2-Negative Breast Cancer
20247 citationsauthor #15
Elasticity Values as a Predictive Modality for Response to Neoadjuvant Chemotherapy in Breast Cancer
20244 citationsauthor #3
Abstract PS16-06: Tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: A single-center real-world study
20240 citationsauthor #9
BRCA1 mutation promotes sprouting angiogenesis in inflammatory cancer-associated fibroblast of triple-negative breast cancer
202411 citationsauthor #7
Clinical Relevance of TP53 Mutation and Its Characteristics in Breast Cancer with Long-Term Follow-Up Date
202411 citationsauthor #6
Stromal tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: a single-center real-world study
20243 citationsauthor #11
Omission of Breast Surgery in Predicted Pathologic Complete Response after Neoadjuvant Systemic Therapy: A Multicenter, Single-Arm, Non-inferiority Trial
202418 citationsauthor #8
Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study.
20242 citationsauthor #10
Abstract PO4-19-10: Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla
20240 citationsauthor #4
Abstract PO5-26-05: Machine learning-based risk prediction for late distant recurrence in young women with estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer
20240 citationsauthor #11
Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Human Epidermal Growth Factor 2-Positive/Triple-Negative Breast Cancer Patients With Excellent Response
202410 citationsauthor #5
De novo versus recurrent metastatic breast cancer affects the extent of brain metastases
20241 citationsauthor #3
Clinical relevance of clinical treatment score post 5 years (CTS5) in HR-positive, HER2-positive breast cancer: An exploratory analysis from the HERA trial.
20240 citationsauthor #7
Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative
20243 citationsauthor #7
Prediction of a Multi-Gene Assay (Oncotype DX and Mammaprint) Recurrence Risk Group Using Machine Learning in Estrogen Receptor-Positive, HER2-Negative Breast Cancer—The BRAIN Study
202412 citationsauthor #2
Luminal androgen receptor subtype and tumor-infiltrating lymphocytes groups based on triple-negative breast cancer molecular subclassification
202410 citationsauthor #7
Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
20248 citationsauthor #11
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study
202427 citationsauthor #51
Predictive Markers of Treatment Response to Neoadjuvant Systemic Therapy with Dual HER2-Blockade
20245 citationsauthor #6
Outcomes of sentinel node biopsy according to MRI response in an association with the subtypes in cN1–3 breast cancer after neoadjuvant systemic therapy, multicenter cohort study
20241 citationsauthor #8
Toripalimab: a new torchlight illuminating the path for metastatic triple negative breast cancer?
20242 citationsauthor #2
Selective omission of sentinel lymph node biopsy in mastectomy for ductal carcinoma in situ: identifying eligible candidates
20245 citationsauthor #9
Abstract PO5-02-09: Discordance of the PAM50 intrinsic subtypes with the immunohistochemistry-based subtypes in HER2-negative early breast cancer treated with neoadjuvant chemotherapy
20240 citationsauthor #3
Capsular Contracture After Postmastectomy Radiation in Implant-Based Breast Reconstruction: Effect of Implant Pocket and Two-Stage Surgery
20244 citationsauthor #11
Micrometastases in axillary lymph nodes in breast cancer, post-neoadjuvant systemic therapy
20248 citationsauthor #8
Long-term oncologic outcome of breast-conserving surgery in breast cancer with BRCA 1/2 mutation (ON-BRCA II, KoREa-BSG 06).
20240 citationsauthor #6
Abstract PO3-23-05: Capsular contracture after post-mastectomy radiotherapy in the patients undergoing implant-based breast reconstruction: impact of implant positioning and two-stage surgery
20240 citationsauthor #14
Tumor-Infiltrating Lymphocyte Level Consistently Correlates with Lower Stiffness Measured by Shear-Wave Elastography: Subtype-Specific Analysis of Its Implication in Breast Cancer
20243 citationsauthor #5
Correction: Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 HR + HER2- breast cancer: a retrospective analysis
20240 citationsauthor #11
Nipple-areolar complex sensory recovery based on incision placement after nipple-sparing mastectomy: a prospective nonrandomized controlled trial
20241 citationsauthor #8
Abstract PO2-01-06: Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in HER2+ early-breast cancer (EBC)
20240 citationsauthor #3
Abstract 1412: Co-existence of TP53 mutation confers endocrine resistance in PIK3CA-mutated ER+HER2- breast cancer
20230 citationsauthor #7
Resolution of Nonmass Enhancement Extension to the Nipple at Breast MRI after Neoadjuvant Chemotherapy: Pathologic Response and Feasibility for Nipple-sparing Mastectomy.
20236 citationsauthor #2
Radiation dose-event relationship after intraoperative radiotherapy as a boost in patients with breast cancer
20231 citationsauthor #5
Comparisons between HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 ER+ HER2- breast cancer.
20230 citationsauthor #1
Complications Including Capsular Contracture in Direct-to-Implant Breast Reconstruction With Textured Anatomical Versus Smooth Round Implants: A Single Center Retrospective Analysis
20235 citationsauthor #5
Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
202336 citationsauthor #14
Abstract P6-01-03: Tumor-infiltrating lymphocytes (TILs) and 21-gene recurrence score in 1,883 patients with ER+/HER2- breast cancer
20230 citationsauthor #1
Selective avoidance of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with HER-2 positive/triple negative breast cancer: Prospective, multi-center, single-arm study (ASLAN).
20232 citationsauthor #4
Knowledge, attitudes, and behaviors toward fertility preservation in patients with breast cancer: A cross-sectional survey of physicians
20235 citationsauthor #10
Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery
202311 citationsauthor #12
YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation
20231 citationsauthor #5
Abstract P2-11-01: Secondary endocrine resistance and high Ki-67 labeling index (≥20%) in patients with low genomic risk identified by 21-gene recurrence score
20230 citationsauthor #9
Omission of breast surgery for predicted pCR patients with MRI and vacuum-assisted biopsy in breast cancer after neoadjuvant chemotherapy: A multicenter, single-arm, non-inferiority trial (OPTIMIST trial).
20238 citationsauthor #10
Prospective single-arm study of endocrine therapies with ovarian function suppression in premenopausal patients with node-positive early breast cancer with low genomic risk (INTERSTELLAR trial, KBCSG-25).
20231 citationsauthor #1
Optimal treatment strategy for hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer patients with 1–2 suspicious axillary lymph node metastases on breast magnetic resonance imaging: upfront surgery vs. neoadjuvant chemotherapy
20236 citationsauthor #2
Abstract P2-14-09: Sensory Evaluation of Nipple-Areolar Complex after Nipple-Sparing Mastectomy: A Comparison of Incision Approaches
20230 citationsauthor #5
Abstract B046: Analyzing heterogeneity of tumor microenvironment of TNBC patients by meta-analysis of 7 breast cancer scRNAseq studies
20231 citationsauthor #4
Sustained prognostic impact of primary tumor characteristics on long-term (overall) survival after distant metastasis in young ER+ HER2- breast cancer.
20230 citationsauthor #9
Additional prognostic value of the BCT score in patients with ER+HER2- breast cancer receiving 21-gene assay–guided adjuvant treatments.
20230 citationsauthor #1
Low tumor-infiltrating lymphocytes of tumors with low genomic risk in women age under 50: analyses of 1,883 ER+/HER2- breast cancer with 21-gene multi-gene assay
20230 citationsauthor #1
Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer
20233 citationsauthor #2
Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1)
20231 citationsauthor #12
Abstract P4-06-08: HER2-protein expression is a predictive marker for treatment response in patients with HER2-positive breast cancer who received neoadjuvant chemotherapy with dual HER2-blockade
20230 citationsauthor #6
Investigation of Factors Affecting Adherence to Adjuvant Hormone Therapy in Early-Stage Breast Cancer Patients: A Comprehensive Systematic Review
202311 citationsauthor #4
Omission of axillary lymph node dissection in patients with HER2-positive or triple-negative breast cancer who had 1-2 sentinel lymph node metastasis after neoadjuvant systemic therapy
20230 citationsauthor #5
Abstract P2-12-13: Pathologic complete response rate according to the carboplatin dose in patients with non-metastatic HER2+ breast cancer treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP)
20220 citationsauthor #8
Correlation of Yes-Associated Protein 1 with Stroma Type and Tumor Stiffness in Hormone-Receptor Positive Breast Cancer
20228 citationsauthor #4
Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
20220 citationsauthor #5
CD39+ tissue-resident memory CD8+ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer
202250 citationsauthor #12
Association of Body Mass Index With 21-Gene Recurrence Score Among Women With Estrogen Receptor–Positive, ERBB2–Negative Breast Cancer
20229 citationsauthor #10
Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
202215 citationsauthor #1
Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
20220 citationsauthor #9
Effects of Single Nucleotide Polymorphisms and Mediterranean Diet in Overweight or Obese Postmenopausal Women With Breast Cancer Receiving Adjuvant Hormone Therapy: A Pilot Randomized Controlled Trial
20225 citationsauthor #8
Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
20223 citationsauthor #2
Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
20220 citationsauthor #1
Abstract P4-05-08: 18F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence
20220 citationsauthor #7
Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP
20222 citationsauthor #9
Abstract P2-13-14: Pattern of recurrence after pathologic complete response after neoadjuvant chemotherapy in patients with early HER2-positive breast cancer: Real-world evidence
20220 citationsauthor #4
Abstract P1-08-11: Clinical relevance of host immunity in patients with breast cancer who received neoadjuvant chemotherapy
20220 citationsauthor #6
Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
20220 citationsauthor #1
Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
202210 citationsauthor #9
RT-induced dynamic changes in the lymphocyte-to-monocyte ratio in patients with breast cancer indicate poor prognosis
20227 citationsauthor #3
Abstract 2542: Unraveling heterogeneity of tumor microenvironment of TNBC patients by meta-analysis of 6 breast cancer scRNAseq studies
20220 citationsauthor #2

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT